1703 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
Rank Status Study
21 Unknown  Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy
Conditions: Lymphoma;   Kikuchi's Disease
Intervention:
22 Recruiting Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Conditions: Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
Interventions: Drug: Rituximab;   Drug: Nelarabine;   Drug: PEG-Asparaginase;   Procedure: Cranial irradiation;   Drug: Imatinib;   Drug: Idarubicin;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Vincristine;   Drug: Mercaptopurine;   Drug: VP16;   Drug: Daunorubicin (DNR);   Drug: Methotrexate;   Procedure: Stem cell transplantation;   Drug: Cytarabine;   Drug: Vindesine;   Drug: Adriamycin;   Drug: Prednisolone
23 Not yet recruiting Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Conditions: B Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   CD19-Positive Neoplastic Cells Present;   Mixed Phenotype Acute Leukemia;   Mixed Phenotype Acute Leukemia With t(9;22)(q34;q11.2); BCR-ABL1
Interventions: Biological: Blinatumomab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
24 Recruiting Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL
Conditions: ALL, Childhood;   Lymphoblastic Leukemia, Acute, Childhood;   Lymphoblastic Leukemia, Acute
Intervention: Drug: Marqibo in combination with UK ALL R3
25 Recruiting Chidamide Combined With Cyclophosphamide、Prednisone、Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma
Condition: Relapse/Refratory Peripheral T Cell Lymphoma
Intervention: Drug: C-CPT
26 Not yet recruiting A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients.
Condition: Follicular Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Venetoclax
27 Not yet recruiting Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Conditions: Leukemia;   Acute Lymphoblastic Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: MESNA;   Drug: Dexamethasone;   Drug: Ofatumumab;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cytarabine;   Drug: Rituximab;   Drug: Pegfilgrastim;   Drug: G-CSF;   Drug: Leucovorin;   Drug: Blinatumomab;   Drug: 6-Mercaptopurine;   Drug: Prednisone;   Behavioral: Phone Calls
28 Not yet recruiting Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Conditions: Acute Leukemia;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Small Lymphocytic Lymphoma
Interventions: Biological: Thymoglobulin;   Drug: Bortezomib;   Drug: Tacrolimus
29 Recruiting Effect of the Number of Needle Revolutions Inside the Node on the Diagnostic Yield of EBUS-TBNA in Sarcoidosis
Condition: Sarcoidosis
Interventions: Procedure: 10 revolutions;   Procedure: 20 revolutions
30 Not yet recruiting Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study
Conditions: Diffuse Large B-cell Lymphoma;   Follicular Lymphoma;   Malignant Rhabdoid Tumors (MRT);   Rhabdoid Tumors of the Kidney (RTK);   Atypical Teratoid Rhabdoid Tumors (ATRT);   Synovial Sarcoma;   Epitheliod Sarcoma;   Mesothelioma;   Advanced Solid Tumors
Intervention: Drug: Tazemetostat
31 Not yet recruiting A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Conditions: Lymphoma, Non-Hodgkin;   Neoplasms
Intervention: Drug: CC-90011
32 Recruiting Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
Conditions: Relapsed Hodgkin Lymphoma;   Relapsed Non-Hodgkin Lymphoma
Interventions: Biological: Pembrolizumab;   Drug: Lenalidomide
33 Not yet recruiting Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Conditions: Relapsed and Refractory Aggressive B- and T-cell Lymphomas;   Lymphoma
Interventions: Drug: volasertib;   Drug: belinostat
34 Not yet recruiting TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: PI3K-delta Inhibitor TGR-1202
35 Recruiting GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
Conditions: Acute Lymphoblastic Leukemia;   Leukemia;   Non-Hodgkin's Lymphoma
Intervention:
36 Recruiting Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
Condition: Diffuse, Large B-Cell, Lymphoma
Interventions: Drug: vindesine;   Drug: cyclophosphamide;   Drug: pirarubicin;   Drug: prednisone tablets;   Drug: Cinobufacini Tablets
37 Not yet recruiting Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Lenalidomide
38 Not yet recruiting Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Conditions: Blastoid Variant Mantle Cell Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Follicular Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis
39 Recruiting Institut Paoli Calmettes Lymphoma Database
Condition: Lymphoma
Intervention: Other: Data collection
40 Recruiting Institut Paoli Calmettes Chronic Lymphatic Leukemia Database
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Other: Data collection

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years